Sign in Subscribe
Cancer research

Favorable Safety Profile for m FBG in Neuroblastoma Patients

Strategic Insights

— 1 min read

New research published in the Nuclear Medicine Communications journal has found a favorable safety profile for the PET radiopharmaceutical m FBG in patients with neuroblastoma. The study, conducted at Memorial Sloan-Kettering Cancer Center, involved 27 patients with neuroblastoma who underwent 18 F-m FBG PET imaging as part of a phase 1/2 trial. The results showed that m FBG administration did not result in any significant changes in vital signs, with only two mild, self-limited adverse events observed. The findings suggest that m FBG has a favorable safety profile for use in patients with neuroblastoma.

Key Takeaways:

  • The study involved 27 patients with neuroblastoma who underwent 18 F-m FBG PET imaging as part of a phase 1/2 trial.
  • The results showed that m FBG administration did not result in any significant changes in vital signs.
  • Only two mild, self-limited adverse events were observed in the study.
  • The findings suggest that m FBG has a favorable safety profile for use in patients with neuroblastoma.
  • The study concluded that the findings are consistent with a favorable safety profile for m FBG in the target population of patients with neuroblastoma.
  • The research was conducted at Memorial Sloan-Kettering Cancer Center and involved a team of researchers led by Ellen Basu and Neeta Pandit-Taskar.
  • Additional authors on the study include Eloisa Balquin, P. David Mozley, Arnold F. Jacobson, and Shakeel Modak.
  • The study was published in the Nuclear Medicine Communications journal in 2024.

Statistics:

  • 27 patients with neuroblastoma were involved in the study.
  • 18 F-m FBG PET imaging was used to assess the patients.
  • 2 mild, self-limited adverse events were observed in the study.
  • No grade 2 or higher adverse events were noted in the study.
  • The study was conducted from April 2015 to January 2022.

Sources:

  • Safety observations in neuroblastoma patients undergoing 18 F- m FBG PET. Nuclear Medicine Communications, 2024;46(3):245-247.
  • NewsRx. Research Data from Memorial Sloan-Kettering Cancer Center Update Understanding of Neuroblastomas (Safety observations in neuroblastoma patients undergoing 18 F- m FBG PET). Clinical Trials Week. October 20, 2025; p 2383.

Read more